Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

November 11, 2024

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

October 10, 2024

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

September 30, 2024

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 13, 2024

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

July 24, 2024

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2024

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2024

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

June 4, 2024

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 9, 2024

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

May 2, 2024

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2024 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top